Trialsribupatidekaileraobesitytype 2 diabetes

Kailera begins Phase 3 of weekly ribupatide in obesity with diabetes

The placebo-controlled trial, NCT07284901, tests KAI-9531 on both percent body weight change and HbA1c, and is listed as active and no longer recruiting.

By Priya Raman · Science Reporter

Oct 6 08:00 ETSource: ClinicalTrials.gov

The wire

01Kailera registered a randomized, double-blind, placebo-controlled Phase 3 study of once-weekly subcutaneous ribupatide (KAI-9531) in adults with obesity or overweight plus diabetes, started January 12, 2026.
02Co-primary endpoints of weight loss and HbA1c place ribupatide directly against established incretins in the diabetes-plus-obesity population clinicians treat most.
03No enrollment size, dose range or readout date appears in the registry entry; the trial is listed as active, not recruiting.

From the source

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901 · PHASE3 · ACTIVE NOT RECRUITING · Sponsor: Kailera · Conditions: Obesity With Diabetes, Overweight With Diabetes.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07284901